Journal
CHEMICAL COMMUNICATIONS
Volume 50, Issue 36, Pages 4659-4673Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4cc00660g
Keywords
-
Categories
Funding
- Camille & Henry Dreyfus Foundation
- National Center for Research Resources [5P20RR016463-12]
- National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103423-12]
- NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016463] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103423] Funding Source: NIH RePORTER
Ask authors/readers for more resources
A substantial obstacle to the existing treatment of bacterial diseases is the lack of specific probes that can be used to diagnose and treat pathogenic bacteria in a selective manner while leaving the microbiome largely intact. To tackle this problem, there is an urgent need to develop pathogen-specific therapeutics and diagnostics. Here, we describe recent evidence that indicates distinctive glycans found exclusively on pathogenic bacteria could form the basis of targeted therapeutic and diagnostic strategies. In particular, we highlight the use of metabolic oligosaccharide engineering to covalently deliver therapeutics and imaging agents to bacterial glycans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available